GlassScriptPhysician profile
Bruce R Saran
NPI 1689674020
$9,376.73
in general payments reported to CMS, 2019-2025
29 companies · $975 in 2025
The $975 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,717 · 2020: $99.27 · 2021: $498 · 2022: $1,962 · 2023: $961 · 2024: $1,165 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,039.44 | 2019-2021 | |
| Abbvie INC. | $1,310.30 | 2022-2025 | Ozurdex |
| Regeneron Healthcare Solutions, INC. | $1,119.45 | 2021-2025 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $948.07 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $716.59 | 2019-2025 | Vabysmo, Lucentis |
| Novartis Pharmaceuticals Corporation | $363.49 | 2019-2023 | |
| Astellas Pharma US INC | $291.98 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $261.48 | 2022-2025 | Xipere, Visudyne, Vyzulta |
| Sun Pharmaceutical Industries INC. | $225.82 | 2019-2025 | |
| Oyster Point Pharma, INC. | $152.74 | 2022-2024 | Tyrvaya |
| Eyepoint US, INC. | $149.72 | 2022-2023 | |
| Alcon Vision LLC | $120.93 | 2020-2025 | Clareon, Tryptyr |
| Dompe US, INC. | $98.89 | 2024-2025 | Oxervate |
| Genentech, INC. | $92.63 | 2019-2024 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.70 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $78.66 | 2024-2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $69.10 | 2025 | Iluvien, Yutiq |
| Shire North American Group INC | $39.55 | 2019 | |
| Harrow Eye, LLC | $37.87 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $32.21 | 2021 | |
| Kala Pharmaceuticals, INC. | $27.55 | 2019 | |
| Glaukos Corporation | $24.50 | 2024 | Radius |
| Rayner Intraocular Lenses Limited | $21.20 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $16.25 | 2024 | |
| Coopervision INC. | $15.81 | 2024 | Myday Contact Lens |
| Apellis Pharmaceuticals, INC. | $15.77 | 2023 | Syfovre |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $4.79 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$90,102.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Saran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.